MeiraGTx Holdings plc
MGTX
Price:
$4.21
Market Cap:
$325.85M
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomi...[Read more]
Industry
Biotechnology
IPO Date
2018-06-08
Stock Exchange
NASDAQ
Ticker
MGTX
The ROE as of September 2024 (TTM) for MeiraGTx Holdings plc (MGTX) is -86.28%
According to MeiraGTx Holdings plc’s latest financial reports and current stock price. The company's current ROE is -86.28%. This represents a change of 210.58% compared to the average of -27.78% of the last 4 quarters.
MeiraGTx Holdings plc (MGTX) Historical ROE (quarterly & annually)
How has MGTX ROE performed in the past?
The mean historical ROE of MeiraGTx Holdings plc over the last ten years is -24.27%. The current -86.28% ROE has changed 255.53% with respect to the historical average. Over the past ten years (40 quarters), MGTX's ROE was at its highest in in the December 2017 quarter at 18.17%. The ROE was at its lowest in in the June 2024 quarter at -60.75%.
Average
-24.27%
Median
-33.18%
Minimum
-121.35%
Maximum
113.70%
MeiraGTx Holdings plc (MGTX) ROE by Quarter and Year
Discovering the peaks and valleys of MeiraGTx Holdings plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 212.58%
Maximum Annual ROE = 113.70%
Minimum Annual Increase = -255.97%
Minimum Annual ROE = -121.35%
| Year | ROE | Change |
|---|---|---|
| 2023 | -60.81% | -49.89% |
| 2022 | -121.35% | 212.58% |
| 2021 | -38.82% | 71.63% |
| 2020 | -22.62% | -17.88% |
| 2019 | -27.54% | -73.06% |
| 2018 | -102.23% | -255.97% |
| 2017 | 65.54% | -42.35% |
MeiraGTx Holdings plc (MGTX) Average ROE
How has MGTX ROE performed in the past?
The current ROE of MeiraGTx Holdings plc (MGTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-73.66%
5-year avg
-54.23%
10-year avg
-24.27%
MeiraGTx Holdings plc (MGTX) ROE vs. Peers
How is MGTX’s ROE compared to its peers?
MeiraGTx Holdings plc’s ROE is greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), less than uniQure N.V. (0%), greater than Rocket Pharmaceuticals, Inc. (-158.09%), greater than Rhythm Pharmaceuticals, Inc. (-54.47%), greater than Solid Biosciences Inc. (-221.66%), greater than Connect Biopharma Holdings Limited (-53.76%), greater than Acumen Pharmaceuticals, Inc. (-3.40%), greater than Eton Pharmaceuticals, Inc. (-24.63%), greater than Nuvation Bio Inc. (-43.62%), greater than Eledon Pharmaceuticals, Inc. (-98.79%), greater than Generation Bio Co. (-124.74%), greater than Kronos Bio, Inc. (-92.86%), greater than Erasca, Inc. (-68.82%), greater than C4 Therapeutics, Inc. (-131.94%), greater than Edgewise Therapeutics, Inc. (-44.60%), greater than null (-28.01%),
| Company | ROE | Market cap |
|---|---|---|
| -20.53% | $3.15B | |
| -255.67% | $1.17B | |
| -44.73% | $2.10B | |
| -100.91% | $3.02M | |
| 0% | $263.45M | |
| -158.09% | $1.77B | |
| -54.47% | $3.02B | |
| -221.66% | $290.62M | |
| -53.76% | $65.75M | |
| -3.40% | $153.80M | |
| -24.63% | $143.65M | |
| -43.62% | $764.57M | |
| -98.79% | $101.92M | |
| -124.74% | $165.18M | |
| -92.86% | $56.02M | |
| -68.82% | $786.77M | |
| -131.94% | $437.87M | |
| -44.60% | $1.59B | |
| -28.01% | $0 |
Build a custom stock screener for MeiraGTx Holdings plc (MGTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MeiraGTx Holdings plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
MeiraGTx Holdings plc (MGTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like MeiraGTx Holdings plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is MeiraGTx Holdings plc's ROE?
How is the ROE calculated for MeiraGTx Holdings plc (MGTX)?
What is the highest ROE for MeiraGTx Holdings plc (MGTX)?
What is the 3-year average ROE for MeiraGTx Holdings plc (MGTX)?
What is the 5-year average ROE for MeiraGTx Holdings plc (MGTX)?
How does the current ROE for MeiraGTx Holdings plc (MGTX) compare to its historical average?